Anti-lair1 antibodies and their uses
AssigneeBoard of Regents, The University of Texas System
InventorsX. Charlene LIAO, Qiang LIU, Zhiqiang AN, Ningyan ZHANG, Xun GUI, Chengcheng ZHANG, Mi DENG, Jingjing XIE
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed to antibodies binding to LAIR 1 and their treating cancer, inflammation, immune-related diseases or transplantation.
Claims63
An isolated monoclonal antibody or an antigen binding fragment thereof, which, when bound to LAIR1, modulates the activity of LAIR1.
An isolated monoclonal antibody or an antigen-binding fragment thereof comprising
- (a) a heavy chain variable region comprising the following complementary determining regions (CDRs):
- a heavy chain CDR1 that is a CDR1 in SEQ ID NO:
- 1, 15, 29, 43, 57, 71, 85, 99, 113, 127, 141, 155, 169, 183, 197, 211, 225, 239, 253, 267, 281, 295, 309, 323, 337, 351, 365, 379, 393, 407, 421, 435, 449, 463, 477, 491, 505 or 519,
- a heavy chain CDR2 that is a CDR2 in SEQ ID NO:
- 1, 15, 29, 43, 57, 71, 85, 99, 113, 127, 141, 155, 169, 183, 197, 211, 225, 239, 253, 267, 281, 295, 309, 323, 337, 351, 365, 379, 393, 407, 421, 435, 449, 463, 477, 491, 505 or 519, and
- a heavy chain CDR3 that is a CDR3 in SEQ ID NO:
- 1, 15, 29, 43, 57, 71, 85, 99, 113, 127, 141, 155, 169, 183, 197, 211, 225, 239, 253, 267, 281, 295, 309, 323, 337, 351, 365, 379, 393, 407, 421, 435, 449, 463, 477, 491, 505 or 519;
- and
- (b) a light chain variable region comprising the following CDRs:
- a light chain CDR1 that is a CDR1 in SEQ ID NO:
- 2, 16, 30, 44, 58, 72, 86, 100, 114, 128, 142, 156, 170, 184, 198, 212, 226, 240, 254, 268, 282, 296, 310, 324, 338, 352, 366, 380, 394, 408, 422, 436, 450, 464, 478, 492, 506 or 520,
- a light chain CDR2 that is a CDR2 in SEQ ID NO:
- 2, 16, 30, 44, 58, 72, 86, 100, 114, 128, 142, 156, 170, 184, 198, 212, 226, 240, 254, 268, 282, 296, 310, 324, 338, 352, 366, 380, 394, 408, 422, 436, 450, 464, 478, 492, 506 or 520, and
- a light chain CDR3 that is a CDR3 in SEQ ID NO:
- 2, 16, 30, 44, 58, 72, 86, 100, 114, 128, 142, 156, 170, 184, 198, 212, 226, 240, 254, 268, 282, 296, 310, 324, 338, 352, 366, 380, 394, 408, 422, 436, 450, 464, 478, 492, 506 or 520.
An isolated monoclonal antibody or an antigen-binding fragment thereof comprising:
- (a) a heavy chain variable region having an amino acid sequence at least about 90% identical to SEQ ID NO:
- 1, 15, 29, 43, 57, 71, 85, 99, 113, 127, 141, 155, 169, 183, 197, 211, 225, 239, 253, 267, 281, 295, 309, 323, 337, 351, 365, 379, 393, 407, 421, 435, 449, 463, 477, 491, 505 or 519;
- and
- (b) a light chain variable region having an amino acid sequence at least about 90% identical to SEQ ID NO:
- 2, 16, 30, 44, 58, 72, 86, 100, 114, 128, 142, 156, 170, 184, 198, 212, 226, 240, 254, 268, 282, 296, 310, 324, 338, 352, 366, 380, 394, 408, 422, 436, 450, 464, 478, 492, 506 or 520.
The isolated monoclonal antibody or an antigen-binding fragment thereof of claim 24, wherein the heavy chain variable region has an amino acid sequence of SEQ ID NO:
- 1, 15, 29, 43, 57, 71, 85, 99, 113, 127, 141, 155, 169, 183, 197, 211, 225, 239, 253, 267, 281, 295, 309, 323, 337, 351, 365, 379, 393, 407, 421, 435, 449, 463, 477, 491, 505 or 519, and wherein the light chain variable region has an amino acid sequence of SEQ ID NO:
- 2, 16, 30, 44, 58, 72, 86, 100, 114, 128, 142, 156, 170, 184, 198, 212, 226, 240, 254, 268, 282, 296, 310, 324, 338, 352, 366, 380, 394, 408, 422, 436, 450, 464, 478, 492, 506 or 520.
Dependencies are inferred from the claim text.